(NYSE:PFE) confirmed this week what everyone has been expecting. COVID-19 vaccine sales are falling drastically. The company reported a 77% drop in Comirnaty sales in the first quarter compared to the same time a year ago. As we head toward a post-pandemic world, demand won't equal that of a pandemic situation.

The big pharmaceutical company also sells coronavirus treatment, Paxlovid. And that product, too, is set to see declines. In fact, Pfizer expects Comirnaty and Paxlovid sales to fall 64% and 58%, respectively, this year. Considering this, should you still buy Pfizer shares? Let's find out.

First, let's talk about the coronavirus portfolio. It's true that coronavirus products have driven growth at Pfizer over the past couple of years. But Pfizer was addressing a pandemic, which is an exceptional situation.

Continue reading

Source Fool.com